Gero

Gero develops a drug discovery platform that combines physics-informed AI with large-scale longitudinal human health data to identify causal targets for age-related diseases. The company utilizes generative models to separate reversible disease processes from irreversible aging, aiming to design molecules and antibody therapies that restore systemic resilience. They collaborate with pharmaceutical partners like Chugai and Pfizer to advance therapeutic programs for complex disorders and fibrotic diseases.